Analytical Data
-
Gene name
BTLA
- Application
-
Alternative Names
CD272; BTLA1; B-and T-lymphocyte-associated protein
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
Q7Z6A9
-
Expression Region
Lys31~Arg157
-
Molecular Weight
18kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BTLA (B and T Lymphocyte Attenuator) is a key immune checkpoint molecule that plays a critical role in modulating the immune response. It belongs to the CD28 family of co-receptors and is mainly expressed on B cells, T cells, and dendritic cells, where it functions as an inhibitory receptor, counteracting signals from costimulatory proteins such as CD28. Research into BTLA has gained significant attention due to its potential implications in cancer immunotherapy, autoimmune diseases, and infectious diseases. In tumor microenvironments, BTLA can inhibit T cell activation and proliferation, leading to immune evasion by cancer cells. This has prompted scientists to investigate the therapeutic potential of targeting BTLA to enhance anti-tumor immunity. Additionally, understanding the mechanisms by which BTLA regulates immune responses could provide insights into developing strategies for treating autoimmune conditions, where the immune system mistakenly attacks healthy tissues. Advances in recombinant protein technology enable the production of functional BTLA proteins for studies that elucidate its structure-function relationship, binding affinities, and downstream signaling pathways. Such studies are essential for developing novel immunotherapeutic approaches that can modulate BTLA signaling, thereby enhancing immune responses against tumors or offering regulatory control in autoimmune disorders. Overall, BTLA represents a promising target for enhancing the efficacy of immunotherapies, necessitating ongoing research to fully elucidate its role in immune regulation.
